Drug Profile
Diazo-oxo-L-norleucine
Alternative Names: DONLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator University of Wisconsin Comprehensive Cancer Center
- Developer University Hospital in Uppsala; University of Wisconsin Comprehensive Cancer Center
- Class Antineoplastics; Azo compounds; Norleucines
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Mesothelioma; Sarcoma
Most Recent Events
- 08 Apr 2003 No development reported - Phase-II for Mesothelioma in USA (IV-infusion)
- 08 Apr 2003 No development reported - Phase-II for Sarcoma in USA (IV-infusion)
- 08 Apr 2003 No development reported - Preclinical for Cancer in Sweden (unspecified route)